Search

Displaying results 641 - 650 of 1101 in total
  1. Drug

    Potassium alum

    go.drugbank.com/drugs/DB09087
    ApprovedWithdrawn

    Potassium alum is considered by the FDA as a generally recognized as safe (GRAS) substance. It is an inorganic salt, also called potassium aluminum sulfate with a formula of AlK(SO4)2 that is predominantly produced in the dodecahydrate f...

  2. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. Bamlanivimab is a neutralizing IgG1κ...

  3. Drug

    Cupric Chloride

    go.drugbank.com/drugs/DB09131
    Approved

    Cupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: Trace Elements Injection USP
  4. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    Lisdexamfetamine is a prodrug of dextroamphetamine, a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodru...

  5. Drug

    Benzethonium

    go.drugbank.com/drugs/DB11125
    Approved

    Its salt form, benzethonium chloride, is primarily used as a skin disinfectant at concentrations of 0.1-0.2 %, which are safe and effective concentrations for the compound specified by the U.S.

  6. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017.

  7. Drug

    Rovatirelin

    go.drugbank.com/drugs/DB15338
    Investigational

    Rovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)).

  8. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

  9. Drug

    Ethylhexyl methoxycrylene

    go.drugbank.com/drugs/DB11226
    Approved

    It currently enjoys regional approvals in Canada, the EU, and the US [L2847].

  10. Drug

    Sorafenib

    go.drugbank.com/drugs/DB00398
    ApprovedInvestigational

    Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approve...